G-CSF-primed peripheral blood progenitor cells (PBPC) support in high-risk Ewing sarcoma of childhood.
Since 1993 pediatric patients affected by high-risk Ewing sarcoma for the presence at onset of a large pelvic mass and/or metastatic disease, were enrolled in a national pilot study comprehensive, finally, of a high-dose chemotherapy (HDCT) procedure with hemopoietic stem cell support. The HDCT procedure considered as consolidation of the disease status obtained after the first-line therapy was followed by the reinfusion of granulokine colony-stimulating factor-primed (G-CSF) peripheral blood progenitor cell (PBPCT). Here we present the results in terms of treatment-related toxicity, hospitalization and rescue of the bone marrow function, in 17 pediatric patients enrolled in such a pilot protocol and submitted to HDCT and PBPCT at the end of first-line therapy.
Prete
A
A
Department of Paediatrics, University of Bologna, Italy.
Rosito
P
P
Alvisi
P
P
Rondelli
R
R
Melchionda
F
F
Magrini
E
E
Pession
A
A
D000293:Adolescent; D000970:Antineoplastic Agents / Q000627:therapeutic use / Q000633:toxicity; D002648:Child; D002675:Child, Preschool; D004305:Dose-Response Relationship, Drug; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D019650:Hematopoietic Stem Cell Mobilization; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006801:Humans; D008297:Male; D009504:Neutrophils / Q000166:cytology; D010865:Pilot Projects; D010976:Platelet Count; D012008:Recurrence; D012307:Risk Factors; D012512:Sarcoma, Ewing / Q000188:drug therapy / Q000401:mortality / Q000628:therapy*; D015996:Survival Rate